Sales representatives for Dyanavel extended-release told physicians the drug worked faster than other ADHD medications and other unproven benefits, according to the lawsuit.
The alleged “false and/or misleading messages regarding the efficacy of Dyanavel XR were disseminated repeatedly on thousands of sales calls to Texas Medicaid providers and decision makers,” the lawsuit says.
A second lawsuit accuses Tris of altering quality control results as tests were showing another ADHD drug, Quillivant, failing to dissolve. Despite this, Pfizer allegedly persuaded Texas’ Medicaid program to add the medication to its list of preferred drugs.
Pfizer said it plans to dismiss the charges.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
